A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...

Please provide your email address to receive an email when new articles are posted on . A blood-based test demonstrated high sensitivity for colorectal cancer among individuals with average risk. The ...

A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...

A blood-based biomarker test, PancreaSure, demonstrated high sensitivity and specificity in differentiating patients with early-stage pancreatic ductal adenocarcinoma (PDAC) from control individuals ...

Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded ...

Progress in cutting the global toll of cancer remains painfully slow, but a new blood test has sparked unusual levels of hope. Researchers say it could one day make routine screening far more ...

Hot off the trail of National Breast Cancer Month in October, one company is trying to ease the detection of the disease that has been projected to impact at least 316,950 women across the country in ...

Cancer remains one of the most formidable public health challenges, causing significant mortality globally. In 2022 alone, there were approximately 19.3 million new cancer diagnoses and 10 million ...

Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).